ESR1 and neoplasm: The WT-ER PDX model was resistant to fulvestrant, but sensitive to capecitabine alone or the combination of fulvestrant and capecitabine, but in this model combining fulvestrant with capecitabine did not impact tumor growth significantly (Fig. 3b).